Invivyd, INC. 8-K Filing
Ticker: IVVD · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $2.50, $2.4999, $117.2 m |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Invivyd, INC. (ticker: IVVD) to the SEC on Nov 19, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar); $2.50 (blic for the Shares in the Offering was $2.50 per Share, and the price to the public); $2.4999 (public for the Pre-Funded Warrants was $2.4999 per Pre-Funded Warrant, which represent); $117.2 m (ny from the Offering were approximately $117.2 million, after deducting underwriting dis).
How long is this filing?
Invivyd, INC.'s 8-K filing is 5 pages with approximately 1,420 words. Estimated reading time is 6 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,420 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2025-11-19 17:23:35
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
- $2.50 — blic for the Shares in the Offering was $2.50 per Share, and the price to the public
- $2.4999 — public for the Pre-Funded Warrants was $2.4999 per Pre-Funded Warrant, which represent
- $117.2 m — ny from the Offering were approximately $117.2 million, after deducting underwriting dis
Filing Documents
- ivvd-20251117.htm (8-K) — 75KB
- ivvd-ex1_1.htm (EX-1.1) — 536KB
- ivvd-ex4_1.htm (EX-4.1) — 180KB
- ivvd-ex5_1.htm (EX-5.1) — 23KB
- ivvd-ex99_1.htm (EX-99.1) — 16KB
- ivvd-ex99_2.htm (EX-99.2) — 17KB
- img59752938_0.jpg (GRAPHIC) — 84KB
- img60430933_0.jpg (GRAPHIC) — 27KB
- img60676459_0.jpg (GRAPHIC) — 84KB
- 0001193125-25-288347.txt ( ) — 1349KB
- ivvd-20251117.xsd (EX-101.SCH) — 31KB
- ivvd-20251117_htm.xml (XML) — 5KB
01
Item 1.01. Entry Into a Material Definitive Agreement. On November 17, 2025, Invivyd, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald & Co., as representative of the underwriters named therein (the "Underwriters"), in connection with its previously announced underwritten public offering (the "Offering") of 44,000,000 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), and, to certain investors, in lieu of Common Stock, pre-funded warrants (the "Pre-Funded Warrants") to purchase 6,000,000 shares of Common Stock. The price to the public for the Shares in the Offering was $2.50 per Share, and the price to the public for the Pre-Funded Warrants was $2.4999 per Pre-Funded Warrant, which represents the price to the public for the Shares less the $0.0001 per share exercise price for each such Pre-Funded Warrant. In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 7,500,000 shares of Common Stock at the same price. The net proceeds to the Company from the Offering were approximately $117.2 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Offering closed on November 19, 2025. The Company intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, for commercial preparedness for the potential launch of VYD2311, continued research and development related to its pipeline programs such as respiratory syncytial virus (RSV) and measles, continued advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and other general corporate purposes. The Underwriting Ag
01
Item 8.01. Other Events. The Company issued press releases announcing the launch and pricing of the Offering on November 17, 2025. Copies of these press releases are filed herewith as Exhibits 99.1 and 99.2, respectively, and are each incorporated by reference into this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated November 17, 2025, by and between Invivyd, Inc. and Cantor Fitzgerald & Co. 4.1 Form of Pre-Funded Warrant to Purchase Common Stock 5.1 Opinion of Hogan Lovells US LLP 23.1 Consent of Hogan Lovells US LLP (contained in Exhibit 5.1) 99.1 Press Release announcing the launch of the Offering, dated November 17, 2025 99.2 Press Release announcing the pricing of the Offering, dated November 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: November 19, 2025 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary